The nation of Zimbabwe has rejected a significant American health deal valued at 367 million US dollars (£272m) spanning five years over the United States' request for confidential information.
The decision was revealed after a internal memorandum dated December was disclosed, revealing that Head of State Emmerson Mnangagwa felt the deal was "lopsided".
A government spokesman has since explained that the US was seeking genetic material for scientific study and commercial purposes but was unwilling to share the resulting advantages from future vaccines.
"We must now begin the difficult and regrettable process of scaling back our health assistance in Zimbabwe," stated American envoy to Zimbabwe Pamela Tremont publicly.
The US Embassy said the United States had donated more than $1.9bn for health programmes to Zimbabwe during the past two decades.
A medical body in Zimbabwe has urged continued negotiations to reach a deal acceptable to both sides so the nation's critical HIV treatment initiative can proceed.
Wider Context
This development comes after a similar situation in Kenya, where a high court suspended a similar deal with the US following concerns were filed about the security of Kenyans' medical information.
Since resuming office last year, US President Donald Trump has drastically cut foreign aid and closed the key foreign aid agency.
The agency had overseen assistance for the US government, but Trump argued its expenditure was "wasteful" and his administration was pursuing government-to-government agreements to boost transparency and responsibility.
According to statements, Sixteen African countries have to date signed these new agreements, representing over $18.3bn of fresh investment.
Details of the Rejected Agreement
The funds for Zimbabwe was intended to funded "tackling HIV/Aids, TB, malaria, maternal and child health, and disease outbreak preparedness.
"It is our view this partnership could have provided significant advantages for the people of Zimbabwe, especially the 1.2 million currently on antiretroviral therapy through American-funded programmes," Tremont commented.
However, official spokesman Nick Mangwana argued the proposed deal was "asymmetrical".
"Zimbabwe was being asked to provide its biological resources and data for a long time, with no equivalent assurance of access to any scientific breakthroughs – like vaccines, diagnostics, or treatments – that could be developed from that provided information," he stated.
"Put simply, our nation would provide the basic resources for scientific discovery without any certainty that the final treatments would be accessible to our citizens should a new disease outbreak arise."
Sovereignty and Global Health
He also said that the American exit from the global health body and its pursuit of bilateral health agreements were disrupting frameworks already established through the international health agency.
Mangwana cited its Pandemic Benefit-Sharing scheme designed to deal with future pandemics.
"This framework is designed to ensure that when a country provides its information, the benefits – such as medicines and cures – are shared equitably, not monopolised solely by those with the resources to develop them."
These objections regarding the US deal "should not be misconstrued as opposition to America," Mangwana stressed.
"We welcome ongoing discussions with our US partners on how future co-operation could be arranged in a manner that respects the sovereignty and dignity of both nations."
Health Experts Reaction
A leading public health body expressed it understood the official position, but urged that negotiations need to persist given that much of the country's HIV programmes relied on international support.
"Where specific concerns exist, including those relating to data governance or implementation frameworks, these can frequently be resolved via detailed discussion and negotiated safeguards," it added.
The situation highlights the complex tensions between accepting vital international aid and protecting a country's data in an ever more data-driven world.